Which drugs should be avoided in patients with myotonic dystrophy?

Drugs to Avoid in Myotonic Dystrophy

Patients with myotonic dystrophy must avoid succinylcholine, volatile anesthetics (halothane, isoflurane, sevoflurane), and anticholinesterase agents like neostigmine, as these can trigger life-threatening complications including rhabdomyolysis, hyperkalemia, cardiac arrest, and severe myotonia.

Critical Contraindications

Anesthetic Agents (Class III: Harm)

Succinylcholine is absolutely contraindicated in myotonic dystrophy patients 1. This depolarizing muscle relaxant disrupts unstable cell membranes and has been directly linked to:

• Acute rhabdomyolysis
• Hyperkalemia
• Sudden cardiac arrest
• Multiple case reports document previously undiagnosed myotonic dystrophy discovered only after sudden death during anesthesia with succinylcholine 1

Volatile anesthetics (halothane, isoflurane, sevoflurane) should be considered contraindicated 1. These agents cause:

• Extreme hyperthermic events mimicking malignant hyperthermia
• Rhabdomyolysis
• Hyperkalemia leading to cardiac arrest
• While genetically distinct from malignant hyperthermia, the clinical presentation is indistinguishable and equally lethal

Neostigmine and other anticholinesterase agents are relatively contraindicated 2, 3. These acetylcholinesterase inhibitors precipitate severe myotonia and should not be used for reversal of neuromuscular blockade. If reversal is needed, sugammadex is the preferred alternative as it encapsulates rocuronium/vecuronium without triggering myotonia 2.

Cardiac Medications

For patients with myotonic dystrophy who develop cardiac involvement:

Avoid in atrial fibrillation:

• Digoxin - potentially harmful in absence of atrial fibrillation 4
• Disopyramide alone (without beta-blockers or verapamil) - enhances AV conduction and increases ventricular rate during AF episodes 4

Avoid in cardiomyopathy with obstruction:

• Pure vasodilators and high-dose diuretics - potentially harmful in patients with resting or provocable outflow tract obstruction 4
• Nifedipine and other dihydropyridine calcium channel blockers - potentially harmful for symptom treatment 4
• Verapamil - potentially harmful in setting of systemic hypotension or severe dyspnea at rest 4

Avoid positive inotropes:

• Dopamine, dobutamine, norepinephrine and other IV positive inotropic drugs are potentially harmful for acute hypotension in obstructive cardiomyopathy 4

Antiarrhythmic Considerations

Class I, II, and IV antiarrhythmic agents can increase peripheral muscular weakness 5. While not absolutely contraindicated, they require careful consideration of the risk-benefit ratio in the context of coexisting conduction abnormalities or myocardial dysfunction.

Mitochondrial-Toxic Agents

Myotonic dystrophy patients should avoid or use with extreme caution 6:

• Propofol - risk of propofol infusion syndrome
• Valproic acid - mitochondrial toxicity
• Statins and fibrates - risk of myopathy
• Some beta-blockers - though may be needed for cardiac management
• Amiodarone - mitochondrial toxicity (though may be necessary for arrhythmia control 7)

Safe Alternatives

For Anesthesia:

• Regional/neuraxial techniques preferred when feasible 8
• Nondepolarizing muscle relaxants (rocuronium, vecuronium) appear safe in myotonic dystrophy type 2 9
• Dexmedetomidine can be used for sedation but start at low doses (0.2 μg/kg/hr maintenance) due to risk of airway obstruction 8
• Sugammadex for reversal of rocuronium/vecuronium 2

For Myotonia Treatment:

• Mexiletine - most potent antimyotonic agent, fast sodium channel blocker 10, 11
• Avoid tocainide - hematologic risks outweigh benefits 10

Critical Clinical Pitfalls

1. Undiagnosed myotonic dystrophy: Many sudden deaths during anesthesia have occurred in patients with previously unrecognized disease 1. Consider screening for myotonic dystrophy in patients with unexplained muscle symptoms before elective procedures.

2. Cardiac involvement is unpredictable: Life-threatening arrhythmias can occur at any disease stage, not just in severe phenotypes 3. Annual cardiac monitoring is recommended even when asymptomatic 12, 13.

3. Progressive conduction disease: Myotonic dystrophy type 1 patients can develop rapid, unpredictable progression of AV block 14, 15. Consider ICD over pacemaker alone when pacing is indicated 14, 15, 13.

4. Drug sensitivity: Patients show hypersensitivity to anesthetic drugs, opioids, and sedatives 1, 8. Always start with lower doses and titrate carefully.